BRD4 inhibitor JQ1 or I-BET151 treatment inhibits GLI1 and GLI2 expression and growth of hedgehog-driven tumors in vitro and in vivo, such as basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor [69,70]. Here, GLI2 is linked to medulloblastoma.